{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:11Z","timestamp":1790239391146,"version":"4.1.0"},"reference-count":5,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; We wanted to evaluate the impact of peritoneal dialysis on trabectedin therapy in terms of side effects, response and levels in the blood and dialysate of a patient on peritoneal dialysis for end-stage renal failure caused by previous ifosfamide therapy. This has not yet been reported in the medical literature. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We measured the levels of trabectedin in the blood and peritoneal dialysate at different time points before and after the administration of a 3rd cycle of trabectedin (1.5 mg\/m&lt;sup&gt;2&lt;\/sup&gt; over 24 h). Toxicity from the treatment was recorded and the response status was evaluated on a CT scan after the 3rd and 6th cycles. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Serum&lt;b&gt; &lt;\/b&gt;creatinine clearance (Cockcroft-Gault formula) was 8.31 ml\/min. The patient had a World Health Organization performance status score of \u20180' and did not suffer any significant side effects except for grade 2 anaemia. There was no difference in the plasma level of trabectedin just before and after a 3-hour session of peritoneal dialysis. The amount of trabectedin in the peritoneal dialysates was undetectable (limit of quantification: 25.9 pg\/ml). The patient achieved stable disease after 3 cycles, and progressive disease was observed after 6 cycles on CT scan. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Our patient did not suffer undue side effects from trabectedin, and peritoneal dialysis did not appear to have an impact on the clearance of the drug.<\/jats:p>","DOI":"10.1159\/000365071","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T06:35:21Z","timestamp":1408689321000},"page":"458-460","source":"Crossref","is-referenced-by-count":4,"title":["Experience with Trabectedin in an Advanced Sarcoma Patient on Peritoneal Dialysis for End-Stage Renal Failure"],"prefix":"10.1159","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-1975","authenticated-orcid":false,"given":"Maung Maung Myat","family":"Moe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez Teruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Soto-Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0263"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1718-5"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0342-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-2902-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000326466"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/365071","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/365071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/365071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:54:47Z","timestamp":1745430887000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000365071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":5,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,9,1]]},"published-print":{"date-parts":[[2014,9,9]]}},"URL":"https:\/\/doi.org\/10.1159\/000365071","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}